Oncolytics Biotech (NASDAQ:ONCY) Rating Reiterated by HC Wainwright
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 441.18% from the company’s current price. Oncolytics […]
More Stories
iShares MSCI Emerging Markets ETF (NYSEARCA:EEM) Shares Sold by XML Financial LLC
XML Financial LLC cut its holdings in shares of iShares MSCI Emerging Markets ETF (NYSEARCA:EEM – Free Report) by 1.7%...
Capricor Therapeutics (CAPR) to Release Quarterly Earnings on Wednesday
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes...
Sheets Smith Wealth Management Buys New Position in SPDR S&P SmallCap 600 ESG ETF (NYSEARCA:ESIX)
Sheets Smith Wealth Management purchased a new position in SPDR S&P SmallCap 600 ESG ETF (NYSEARCA:ESIX – Free Report) during...
Sheets Smith Wealth Management Decreases Stake in The Estée Lauder Companies Inc. (NYSE:EL)
Sheets Smith Wealth Management cut its holdings in shares of The Estée Lauder Companies Inc. (NYSE:EL – Free Report) by...
Sheets Smith Wealth Management Sells 1,344 Shares of Kirby Co. (NYSE:KEX)
Sheets Smith Wealth Management trimmed its stake in shares of Kirby Co. (NYSE:KEX – Free Report) by 33.1% during the...
National Bank Financial Predicts BIP FY2025 Earnings
Brookfield Infrastructure Partners L.P. (NYSE:BIP – Free Report) (TSE:BIP.UN) – National Bank Financial boosted their FY2025 EPS estimates for shares...